[HTML][HTML] Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of …
Background Innovations in imaging and molecular characterisation and the evolution of new
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue …
Genetic and genomic testing for prostate cancer: beyond DNA repair
Significant progress has been made in genetic and genomic testing for prostate cancer
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …
across the disease spectrum. Molecular profiling is increasingly relevant for routine clinical …
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation …
CC Parker, H Kynaston, AD Cook, NW Clarke… - The Lancet, 2024 - thelancet.com
Background Previous evidence supports androgen deprivation therapy (ADT) with primary
radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer …
radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer …
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation …
CC Parker, NW Clarke, AD Cook, H Kynaston… - The Lancet, 2024 - thelancet.com
Background Previous evidence indicates that adjuvant, short-course androgen deprivation
therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for …
therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for …
[HTML][HTML] Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)
CC Parker, PM Petersen, AD Cook, NW Clarke… - Annals of …, 2024 - Elsevier
Background The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate
cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT …
cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT …
[HTML][HTML] Randomised trial of no, short-term, or long-term androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy: Results from the …
CC Parker, NW Clarke, AD Cook, PM Petersen… - European urology, 2024 - Elsevier
Background and objective The use and duration of androgen deprivation therapy (ADT) with
postoperative radiotherapy (RT) have been uncertain. RADICALS-HD compared adding no …
postoperative radiotherapy (RT) have been uncertain. RADICALS-HD compared adding no …
[PDF][PDF] Evaluation of specific lncRNAs, miRNAs, and mRNAs in different groups of prostate cancer
G Vahabzadeh, A Pashapour-Yeganeh, M Eini… - 2025 - bi.tbzmed.ac.ir
Introduction: LncRNAs interact with miRNAs and mRNAs that can have a special expression
pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in …
pattern in a specific cell type. We investigated the specific lncRNAs, miRNAs, and mRNAs in …